Company / SG&A Expense
AYTU BIOPHARMA, INC SG&A Expense History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$17.4M
FY2025
5-year range
$17.4M / $31.2M
FY2021-FY2025
Trend
-12.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $31M in FY2022 to $17M in FY2025.
Based on SEC 10-K filings.
$17M in FY2025 with a 10-year CAGR of +15.9%.
Improved from $29M to $17M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -17.7%
- 5-Year CAGR
- -13.0%
- 10-Year CAGR
- +15.9%
Key checks
Key Insights
- AYTU BIOPHARMA, INC's sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of -13.0%, indicating a declining trend.
- In FY2025, sg&a expense decreased 12.9% year-over-year.
- Peak sg&a expense was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.4M | -12.9% |
| FY2024 | $20.0M | -30.3% |
| FY2023 | $28.6M | -8.1% |
| FY2022 | $31.2M | +22.2% |
| FY2021 | $25.5M | -26.7% |
| FY2020 | $34.8M | +96.3% |
| FY2018 | $17.7M | +1.7% |
| FY2017 | $17.4M | +104.8% |
| FY2016 | $8.5M | +114.0% |
| FY2015 | $4.0M | +1065.7% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026